Biopharmaceutical company PTC Therapeutics Inc (NASDAQ: PTCT) announced on Monday that the US Food and Drug Administration (FDA) has approved SEPHIENCE (sepiapterin) for the treatment of children and adults living with phenylketonuria (PKU).
This approval includes broad labelling for the treatment of hyperphenylalaninemia (HPA) in adult and paediatric patients 1 month of age and older with sepiapterin-responsive PKU.
PKU is a rare, inherited metabolic disease, which affects the brain.
The FDA approval is based on evidence of significant efficacy and safety from the Phase 3 APHENITY trial as well as durability of treatment effect in the APHENITY long-term extension study.
SEPHIENCE was recently granted marketing authorisation by the European Commission. Review of approval applications is ongoing in several other countries including Japan and Brazil.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval